Ervaxx is illuminating the immune interface to develop new cancer therapies.
Enara Bio has raised $32.5M in total funding. The most recent round was Series B. The last funding was announced in October 2024.
Enara Bio's investors include RA Capital Management, Samsara BioCapital, Pfizer Venture Investments, SV Health Investors, M Ventures.
Enara Bio is headquartered in Oxford, United Kingdom.
Ervaxx is illuminating the immune interface to develop new cancer therapies.
Enara Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Enara Bio — Funding & Investors." VCBacked, October 3, 2024, https://www.vcbacked.co/company/enara-bio. Accessed November 13, 2026.
VCBacked. (2024). Enara Bio — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/enara-bio
{{cite web |title=Enara Bio — Funding & Investors |url=https://www.vcbacked.co/company/enara-bio |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Enara Bio? Request a listing update